Shattuck Labs (STTK) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

STTK Shattuck Labs

Watchlist

1.180
0.0000.00%

Close Nov 11 16:00 ET

1.170
-0.010-0.85%

Post 17:01 ET

56.32MMarket Cap-637P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Shutterstock CFO Jarrod Yahes Leaving; Rik Powell, Currently Senior Vice President Of Finance And Investor Relations, Named Next CFO
BenzingaOct 29 09:24 ET
Insider Stock Research: New Fortress Energy, Marvell, and More
Quiver QuantitativeOct 21 16:58 ET
GXO Logistics, Momentus, Shattuck Labs: 3 Stocks Retail Investors Are Most Bullish On Today
BarchartOct 10 11:46 ET
After Plunging -68.96% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)
Zacks Oct 8 09:00 ET
Citi Downgrades Shattuck Labs(STTK.US) to Hold Rating, Cuts Target Price to $2
Moomoo NewsOct 3 07:31 ET · Ratings
Evercore Maintains Shattuck Labs(STTK.US) With Buy Rating
Moomoo NewsOct 2 14:33 ET · Ratings

Comments

Johnny Mnemonic

Oct 2 08:47

quit selling u stupid fks

Jaguar8

Oct 1 05:50

NEWS

$Shattuck Labs (STTK.US)$
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
Shattuck Labs (Nasdaq: STTK) announced a strategic pipeline prioritization, discontinuing its SL-172154 clinical program due to modest improvements in overall survival for TP53 mutant AML and HR-MDS patients. The company will focus on SL-325, a first-in-class DR3 antagonist antibody for inflammatory bowel disease (IBD...

Trytosaveabit

Jun 26 16:05

Insider buy

$Shattuck Labs (STTK.US)$ Officer Schreiber Taylor purchased 14,400 shares of common stock on Jun 26, 2024 at an average price of $3.473 for a total value of $50,011.2.

Trytosaveabit

Jun 14 05:34

Update

$Shattuck Labs (STTK.US)$ Shattuck Labs, Discloses Updated Interim Data From Phase 1B Dose Expansion Clinical Trial Of SL-172154 In Combination With Azacitidine In Frontline Higher-Risk Myelodysplastic Syndromes And TP53 Mutant Acute Myeloid Leukemia Patients
Benzinga
The company observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had no...